Physician profile
Kiran Bath
NPI 1689831380
$20,078.47
in general payments reported to CMS, 2019-2025
49 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 89% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $5,798 · 2021: $6,152 · 2022: $1,026 · 2023: $1,807 · 2024: $3,722 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,083 · Travel and Lodging: $1,524 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,082.97 |
| Travel and Lodging | $1,524.40 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,458.33 | 2020-2021 | |
| Abbvie INC. | $5,677.21 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Abbott Laboratories | $2,188.21 | 2024-2025 | Infinity |
| Novartis Pharmaceuticals Corporation | $1,052.93 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $464.30 | 2021-2025 | Ultomiris, Soliris |
| Csl Behring | $402.76 | 2020-2025 | Hizentra |
| Ucb, INC. | $318.01 | 2022-2025 | Briviact, Nayzilam |
| Biogen, INC. | $305.03 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Lilly USA, LLC | $288.40 | 2021-2024 | Amyvid, Kisunla, Emgality |
| Argenx US, INC. | $251.81 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $240.65 | 2021-2025 | |
| Pfizer INC. | $230.20 | 2023-2025 | |
| Celgene Corporation | $215.35 | 2022-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $180.11 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Acadia Pharmaceuticals INC | $169.95 | 2023-2025 | Nuplazid |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Bath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.